Here are a few Frequently Asked Questions (FAQs) about Pharmacovigilance and Gap Analysis.
What is Pharmacovigilance (PV) Gap Analysis?
A gap analysis in Pharmacovigilance (PV) is a structured review of current processes and systems. It also involves reviewing outcomes against global or applicable regulations (e.g., FDA, EMA, ICH, GVP) or internal policies to identify gaps in processes, so PV teams can address the improvement needs.
Why is PV Gap Analysis Important for MAHs or CROs?
Global regulations, product portfolios, and vendors change over time. To be inspection-ready and compliant with the markets they seek to enter, Pharmacovigilance gap analysis is essential for Market Authorization Holders (MAHs) and Contract Research Organizations (CROs). The analysis can push for proper PSMF maintenance, accurate signal management, and timely case processing, mitigating risks such as critical findings and product holds.
When should you go for Pharmacovigilance Gap Analysis?
Usually, new product launches, major acquisitions, regulatory changes, or updates prompt a pharmacovigilance gap analysis. Findings from previous audits can also trigger PV gap analysis.
What are the core areas covered in PV gap analysis?
To be precise, every key area is covered in PV gap analysis. To list a few, check out the governance processes, responsibilities of a QPPV, content of the PSMF, coding, signal management, safety database configuration, and documentation control, such as SoPs and templates.
What are the typical gaps in Pharmacovigilance Systems?
One should maintain clarity, consistency, adequacy, and completeness of their PV systems to be compliant. Common gaps in PV systems include outdated PSMFs, inadequate signal detection, unclear oversight of QPPV, late ICSR submissions, inconsistent records, etc. Also, misaligned SoPs against actual practice, poor or sometimes absent documentation, and other gaps are among the most common issues found in Pharmacovigilance systems.
What is the typical process of Pharmacovigilance Gap Analysis?
The usual process starts with collecting data, such as PSMFs, SoPs, metrics, and audit reports; mapping and reviewing them end-to-end; and conducting key stakeholder and PV expert interviews. Findings are then pushed for risk and regulatory impact classification as per the critical, major, and minor classifications, followed by the development of a proper corrective and preventive action plan (CAPA).
The FAQ list for Pharmacovigilance gap analysis we have provided here is collated from the common queries we received. However, we would like to assure you that our PV experts are willing to answer any unique queries you have that are not listed above. Please write to us at <email>, or for an exclusive consultation or a quick call, schedule an appointment here < meeting scheduler>.
Comments are closed